HUP0302336A2 - 5-Klór-3-(4-metánszulfonilfenil)-6'-metil-[2,3']bipiridinil tiszta formában és eljárás előállítására - Google Patents

5-Klór-3-(4-metánszulfonilfenil)-6'-metil-[2,3']bipiridinil tiszta formában és eljárás előállítására

Info

Publication number
HUP0302336A2
HUP0302336A2 HU0302336A HUP0302336A HUP0302336A2 HU P0302336 A2 HUP0302336 A2 HU P0302336A2 HU 0302336 A HU0302336 A HU 0302336A HU P0302336 A HUP0302336 A HU P0302336A HU P0302336 A2 HUP0302336 A2 HU P0302336A2
Authority
HU
Hungary
Prior art keywords
methanesulfonylphenyl
bipyridinyl
chloro
methyl
synthesis
Prior art date
Application number
HU0302336A
Other languages
English (en)
Inventor
Louis S. Crocker
Ian W. Davies
Andrew Kotliar
Richard G. Osifchin
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302336(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of HUP0302336A2 publication Critical patent/HUP0302336A2/hu
Publication of HU228423B1 publication Critical patent/HU228423B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány az (A) képletű 5-klór-3-(4-metánszulfonilfenil)-6'-metil[2,3']bipiridinil vegyület V formájú polimorfjára vonatkozik,mely polimorf forma felhasználható ciklooxigenáz 2 által közvetítettmegbetegedések kezelésére. A találmány továbbá olyan, ciklooxigenáz 2által közvetített megbetegedések kezelésére alkalmas gyógyászatikészítményekre vonatkozik, amelyek nemtoxikus, terápiásan hatásosmennyiségben az (A) képletű vegyület V polimorf formáját tartalmazzák.Végül a találmány tárgya eljárás az (A) képletű vegyület V polimorfformájának előállítására. Ó
HU0302336A 2000-05-26 2001-05-22 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis HU228423B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26
PCT/US2001/016566 WO2001092230A1 (en) 2000-05-26 2001-05-22 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis

Publications (2)

Publication Number Publication Date
HUP0302336A2 true HUP0302336A2 (hu) 2003-11-28
HU228423B1 HU228423B1 (en) 2013-03-28

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302336A HU228423B1 (en) 2000-05-26 2001-05-22 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis

Country Status (49)

Country Link
EP (1) EP1296951B1 (hu)
JP (2) JP3665053B2 (hu)
KR (1) KR100757699B1 (hu)
CN (1) CN1227233C (hu)
AR (1) AR028577A1 (hu)
AT (1) ATE483687T1 (hu)
AU (2) AU6480401A (hu)
BG (1) BG65855B1 (hu)
BR (1) BRPI0111140B8 (hu)
CA (1) CA2410234C (hu)
CR (1) CR6606A (hu)
CY (1) CY1111440T1 (hu)
CZ (1) CZ20023888A3 (hu)
DE (1) DE60143197D1 (hu)
DK (1) DK1296951T3 (hu)
EA (1) EA004809B1 (hu)
EE (1) EE05242B1 (hu)
EG (1) EG24189A (hu)
ES (1) ES2351958T3 (hu)
GC (1) GC0000362A (hu)
GE (1) GEP20053492B (hu)
GT (1) GT200100091A (hu)
HK (1) HK1058932A1 (hu)
HN (1) HN2001000110A (hu)
HR (1) HRP20020934B1 (hu)
HU (1) HU228423B1 (hu)
IL (1) IL152582A0 (hu)
IN (2) IN2002CH02089A (hu)
IS (1) IS2806B (hu)
JO (1) JO2216B1 (hu)
MA (1) MA26919A1 (hu)
ME (1) ME00428B (hu)
MX (1) MX230696B (hu)
MY (1) MY123569A (hu)
NO (1) NO324495B1 (hu)
NZ (1) NZ522394A (hu)
PA (1) PA8516901A1 (hu)
PE (1) PE20011324A1 (hu)
PH (1) PH12001001175B1 (hu)
PL (1) PL358153A1 (hu)
PT (1) PT1296951E (hu)
RS (1) RS51541B (hu)
SI (1) SI1296951T1 (hu)
SK (1) SK287174B6 (hu)
SV (1) SV2002000462A (hu)
TW (1) TWI303634B (hu)
UA (1) UA73355C2 (hu)
WO (1) WO2001092230A1 (hu)
ZA (1) ZA200209558B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4425514B2 (ja) 1999-11-29 2010-03-03 メルク フロスト カナダ リミテツド ５−クロロ−３−（４−メタンスルホニルフェニル）−６′−メチル−［２，３′］ビピリジニルの多形型、非晶質型および水和型
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
HUE028730T2 (hu) 2009-02-27 2017-01-30 Cadila Healthcare Ltd Folyamat etoricoxib elõállítására
WO2012004677A1 (en) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
PL2714676T3 (pl) 2011-05-27 2019-10-31 Farma Grs D O O Sposób wytwarzania formy polimorficznej I etorykoksybu
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
EP2888231B1 (en) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
EP2887924B1 (en) 2012-08-27 2017-03-29 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
MX2017009660A (es) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
BRPI9710372B8 (pt) * 1996-07-18 2021-05-25 Merck Canada Inc composto, e, composição farmacêutica.
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
PT1071745E (pt) * 1998-04-24 2004-11-30 Merck & Co Inc Processo para sintetizar inibidores cox-2
JP4425514B2 (ja) * 1999-11-29 2010-03-03 メルク フロスト カナダ リミテツド ５−クロロ−３−（４−メタンスルホニルフェニル）−６′−メチル−［２，３′］ビピリジニルの多形型、非晶質型および水和型

Also Published As

Publication number Publication date
JP2004501116A (ja) 2004-01-15
HK1058932A1 (en) 2004-06-11
BRPI0111140B8 (pt) 2021-05-25
NO324495B1 (no) 2007-10-29
ZA200209558B (en) 2003-10-28
EA004809B1 (ru) 2004-08-26
IS2806B (is) 2012-09-15
BG107237A (bg) 2003-05-30
SI1296951T1 (sl) 2011-01-31
AU6480401A (en) 2001-12-11
PE20011324A1 (es) 2002-01-28
EE05242B1 (et) 2009-12-15
KR20030003762A (ko) 2003-01-10
CN1227233C (zh) 2005-11-16
SV2002000462A (es) 2002-03-08
AU2001264804B2 (en) 2006-04-06
SK287174B6 (sk) 2010-02-08
CY1111440T1 (el) 2015-08-05
PL358153A1 (en) 2004-08-09
CA2410234C (en) 2008-05-13
PT1296951E (pt) 2010-12-07
JP3665053B2 (ja) 2005-06-29
EP1296951B1 (en) 2010-10-06
SK16702002A3 (sk) 2003-05-02
MX230696B (es) 2005-09-19
CA2410234A1 (en) 2001-12-06
IL152582A0 (en) 2003-05-29
DE60143197D1 (de) 2010-11-18
JO2216B1 (en) 2004-10-07
CN1443168A (zh) 2003-09-17
CR6606A (es) 2006-02-06
JP4142621B2 (ja) 2008-09-03
EP1296951A1 (en) 2003-04-02
MY123569A (en) 2006-05-31
PH12001001175B1 (en) 2006-08-10
DK1296951T3 (da) 2011-01-24
NZ522394A (en) 2004-05-28
EG24189A (en) 2008-10-08
ES2351958T3 (es) 2011-02-14
GC0000362A (en) 2007-03-31
IN2002CH02089A (hu) 2005-02-25
IS6630A (is) 2002-11-20
HRP20020934B1 (en) 2012-01-31
PA8516901A1 (es) 2002-04-25
ATE483687T1 (de) 2010-10-15
MA26919A1 (fr) 2004-12-20
AR028577A1 (es) 2003-05-14
BRPI0111140B1 (pt) 2018-03-13
TWI303634B (en) 2008-12-01
HN2001000110A (es) 2002-03-06
KR100757699B1 (ko) 2007-09-13
NO20025674L (no) 2002-11-26
NO20025674D0 (no) 2002-11-26
RS51541B (sr) 2011-06-30
EA200201264A1 (ru) 2003-04-24
ME00428B (me) 2011-10-10
EE200200655A (et) 2004-08-16
IN2007CH05103A (hu) 2008-08-27
HRP20020934A2 (en) 2005-02-28
MXPA02011619A (es) 2003-03-27
BR0111140A (pt) 2005-01-11
WO2001092230A1 (en) 2001-12-06
JP2005047927A (ja) 2005-02-24
BG65855B1 (bg) 2010-03-31
GEP20053492B (en) 2005-04-25
CZ20023888A3 (cs) 2003-02-12
HU228423B1 (en) 2013-03-28
UA73355C2 (en) 2005-07-15
GT200100091A (es) 2001-12-28
YU89402A (sh) 2005-11-28

Similar Documents

Publication Publication Date Title
HUP0302336A2 (hu) 5-Klór-3-(4-metánszulfonilfenil)-6'-metil-[2,3']bipiridinil tiszta formában és eljárás előállítására
DK1326613T3 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
CA2260016A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
MY138352A (en) Benzothiazole derivatives
HUP0100348A2 (hu) Hattagú, egy vagy két nitrogénatomot tartalmazó kondenzál biciklusok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények, valamint intermedierek
WO2005011654A3 (en) Pyridyl derivatives and their use as therapeutic agents
WO2003082853A8 (en) New compounds
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
WO2005030753A3 (en) Therapeutic agents useful for treating pain
CA2301742A1 (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
WO2002051983A3 (en) Novel compounds and compositions as cathepsin inhibitors
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
WO2002100818A3 (en) Aminediols as agents for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO. INC., US

GB9A Succession in title

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO. INC., US; MERCK SHARP & DOHME CORP., US; SCHERING CORPORATION, US

HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO. INC., US; MERCK SHARP & DOHME CORP., US; SCHERING CORPORATION, US